Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Selux Diagnostics
AddedFeb 15, 2024
UpdatedJun 18, 2026
Selux Diagnostics

Selux Diagnostics

Series A

Selux Diagnostics, Inc. designs automated software solutions for AST results and susceptibility testing in the US.

HQ
Charlestown, MA, US
Founded
2014
Overview
Compare
Fundraising
Employees
Website

Founded with the mission to revolutionize clinical diagnostics, Selux Diagnostics, Inc. focuses on developing advanced software solutions for automated antimicrobial susceptibility testing (AST). Their core vision is to enhance the speed and accuracy of susceptibility testing to combat antibiotic resistance effectively. The company's flagship product, the Selux NGP System, provides rapid AST results and same-shift susceptibility testing, catering primarily to healthcare providers in the United States.

Selux Diagnostics has garnered attention through notable FDA clearance for its Selux NGP System, marking a significant milestone in rapid AST technology. The company collaborates with leading healthcare professionals and institutions to refine its offerings continually. By addressing one of the most pressing medical challenges—antibiotic resistance—Selux Diagnostics has made a substantial impact on improving patient outcomes and optimizing antibiotic use in clinical settings.

Selux Diagnostics - Quick Facts

When was Selux Diagnostics founded?

Selux Diagnostics was founded in 2014.

Where is Selux Diagnostics' headquarters located?

Selux Diagnostics' headquarters is located in Charlestown, MA, US.

When was Selux Diagnostics' last funding round?

Selux Diagnostics' most recent funding round was for $8M (USD) in July 2022.

How much has Selux Diagnostics raised to-date?

As of Jul 12, 2022, Selux Diagnostics has raised a total of $172.5M (USD).

How many employees does Selux Diagnostics have?

Selux Diagnostics has 70 employees as of Feb 5, 2024.

Selux Diagnostics - Classification

Ownership
  • Venture Capital
Technology
  • Analytics
  • Automation
Geographic Exposure
  • United States
Model
  • Platform
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Diagnostics
  • Software
Tags
  • Biotech
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
ISIC
  • 7210Research and experimental development on natural sciences and engineering
Show 17 more industry codes
NAICS
  • 513200Software Publishers
  • 541500Computer Systems Design and Related Services
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 623000Nursing and Residential Care Facilities
  • 513210Software Publishers
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
  • 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SIC
  • 7300Business Services
  • 8000Health Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 8040Offices And Clinics Of Other Health Practitioners
  • 7371Computer Programming Services
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified